Abstracts Archive - Page 1117 of 2607 - ACR Meeting Abstracts

Abstract Number: 2654 • 2019 ACR/ARP Annual Meeting
Comparison of Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair
Laarni Quimson ¹, Adam Mayer², Sarah Capponi ², Bryan Rea ³ and Rennie Rhee ⁴, ¹University of Pennsylvania, Division of Internal Medicine, Philadelphia, PA, ²University of Pennsylvania, Internal Medicine/Pediatrics Residency Program, Philadelphia, PA, ³University of Pittsburgh, Department of Pathology, Pittsburgh, PA, ⁴University of Pennsylvania, Division of Rheumatology, Philadelphia, PA
Background/Purpose: Aortitis is challenging to diagnose and is often detected on surgical pathology. A subset of these patients could benefit from early medical therapy as…
Abstract Number: 2655 • 2019 ACR/ARP Annual Meeting
Large Vessel Vasculitis: Diagnosis Is Very Frequent with Ultrasound Examination and Shows Responsiveness to Treatment
Eugenio de Miguel¹, Irene Monjo ², Elisa Fernández ³, Diana Peiteado ⁴, Chamaida Plasencia ⁵ and Alejandro Balsa ⁵, ¹Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ²FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ³Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, ⁵Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly. In the EULAR recommendations of 2018 for the use of imaging…
Abstract Number: 2656 • 2019 ACR/ARP Annual Meeting
The Veterans Health Administration (VHA) National Database Cohort: Incident Ophthalmic Complications in Giant Cell Arteritis (GCA) Patients with a Negative Temporal Artery Biopsy
Sarah Chung¹, Meredith Morcos ², Scott Pollock ¹ and Bernard Ng ³, ¹University of Washington Division of Rheumatology, Seattle, WA, ²University of Washington Division of Rheumatology, Seattle, ³University of Washington, Veterans Affairs Puget Sound Health Care System, Seattle, WA
Background/Purpose: This study aimed to identify the incidence of ophthalmic complication of giant cell arteritis (GCA) among subjects with negative temporal artery biopsy (TAB) and to…
Abstract Number: 2657 • 2019 ACR/ARP Annual Meeting
The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study
Salman Mahmood¹, Yuanyuan Ji ², Yi Peng ² and Zaki Abou Zahr ¹, ¹Hennepin Healthcare, Minneapolis, MN, ²Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN
Background/Purpose: Bisphosphonates have been used to treat disorders of bone metabolism for several years. A common adverse reaction associated with their use constitutes a transient…
Abstract Number: 2658 • 2019 ACR/ARP Annual Meeting
Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries
Alicia Rodriguez-Pla¹, Lili Zhou ², Erin Ashbeck ³ and C. Kent Kwoh ⁴, ¹University of Arizona/Banner Health Medical Center, Tucson, AZ, ²The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, Tucson, AZ, ³The University of Arizona Arthritis Center, University of Arizona, Tuccson, AZ, Tucson, AL, ⁴University of Arizona, Tucson, AZ
Background/Purpose: Giant cell arteritis (GCA) has traditionally been diagnosed by a combination of symptoms, clinical findings, laboratory results, and temporal artery biopsy. More recently, imaging…
Abstract Number: 2659 • 2019 ACR/ARP Annual Meeting
Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study
Matthias Papo¹, Laure Delaval ¹, Hubert de BOYSSON ², Jean-François Viallard ³, Aurélie Foucher ⁴, Sébastien Humbert ⁵, Pierre Duffau ⁶, Anne Contis ⁷, Christian Agard ⁸, Claude Bachmeyer ⁹, Bruno Gombert ¹⁰, Loic Guillevin ¹¹, Maxime Samson ¹² and Benjamin Terrier ¹¹, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²University Hospital of Caen, Caen, France, ³CHU Bordeaux, Bordeaux, France, ⁴Department of Internal Medicine and Infectious Diseases, Centre Hospitalier Universitaire de la Réunion Saint Pierre, Reunion Island, France., Saint-Pierre, France, ⁵Department of internal medicine, CHU Jean Minjoz, Besancon, France, Besancon, France, ⁶Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France., Bordeaux, Aquitaine, France, ⁷Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France, Bordeaux, France, ⁸CHU Nantes, Nantes, France, ⁹Department of Internal Medicine, Tenon Hospital (AP-HP), Paris, France, Paris, France, ¹⁰Rheumatology Department, Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, France., La Rochelle, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ¹²CHU Dijon, Dijon, France
Background/Purpose: Giant-cell arteritis (GCA) is a large-vessel vasculitis affecting patients >50 years, whose origin remains widely unelucidated. Recent studies demonstrated that myeloid disease-related somatic mutations…
Abstract Number: 2660 • 2019 ACR/ARP Annual Meeting
Rationalizing the Use of MRI of the Scalp Arteries in the Diagnosis of Giant Cell Arteritis Through Multivariable Predictive Modelling
Mats Junek¹, Angela Hu ², Karen Beattie ³, Kimberly Legault ³, Stephanie Garner ⁴, Ryan Rebello ³ and Nader A. Khalidi ³, ¹McMaster University, Oakville, ²University of Toronto, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, Canada
Background/Purpose: It has been historically difficult to develop effective diagnostic strategies and criteria in giant cell arteritis (GCA). While temporal artery biopsy was previously thought…
Abstract Number: 2661 • 2019 ACR/ARP Annual Meeting
A Ten-Year Retrospective Review of Temporal Artery Biopsy Lengths in Alberta
Raymond Chu¹, Caylea Foster ², Mohsin Ali ³, Todd Chaba ¹, Jason Soo ¹, Alison Clifford ¹, Jan Willem Cohen Tervaert ¹ and Elaine Yacyshyn ¹, ¹University of Alberta, Edmonton, Canada, ²University of Calgary, Calgary, Canada, ³Harvard, Boston, MA
Background/Purpose: Temporal arteritis or giant cell arteritis (GCA) is a large vessel vasculitis that involves extracranial arteries. The historical gold standard for diagnosis is a…
Abstract Number: 2662 • 2019 ACR/ARP Annual Meeting
Temporal Artery Biopsy Lengths in Alberta: Which Surgical Subspecialty Achieves Optimal Biopsy Lengths?
Raymond Chu¹, Caylea Foster ², Mohsin Ali ³, Todd Chaba ¹, Jason Soo ¹, Alison Clifford ¹, Jan Willem Cohen Tervaert ¹ and Elaine Yacyshyn ¹, ¹University of Alberta, Edmonton, Canada, ²University of Calgary, Calgary, Canada, ³Harvard, Boston, MA
Background/Purpose: Temporal arteritis or giant cell arteritis (GCA) is a large vessel vasculitis that involves extracranial arteries. Diagnosis requires a combination of clinical manifestations including…
Abstract Number: 2663 • 2019 ACR/ARP Annual Meeting
Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial
John Stone¹, Jian Han ², Sebastian Unizony ¹, Martin Aringer ³, Daniel Blockmans ⁴, Elisabeth Brouwer ⁵, Maria C. Cid ⁶, Bhaskar Dasgupta ⁷, Jürgen Rech ⁸, Carlo Salvarani ⁹, Robert Spiera ¹⁰ and Min Bao ², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA, ³Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁴Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁵Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ⁷Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁰Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with giant cell arteritis (GCA) treated with tocilizumab (TCZ) plus prednisone tapering achieved higher rates of sustained glucocorticoid (GC)-free remission and had lower…
Abstract Number: 2664 • 2019 ACR/ARP Annual Meeting
Color Doppler Ultrasound for the Diagnosis of Giant Cell Arteritis in Montreal: A Canadian Single Center Experience
Jean-Paul Makhzoum¹, Meriem Belhocine ¹, Michelle Goulet ¹, Maxime Rheaume ¹, Tara Starnino ², Stephanie Ducharme-Benard ², Guillaume Febrer ³, Yves Troyanov ⁴, Nathalie Routhier ⁵, Rosalie-Selene Meunier ⁵, Isabelle Chagnon ⁵, Michel Laurier ⁵, Maggy Helou ⁵, Nathalie Morency ⁶ and Anne-Marie Mansour ¹, ¹Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ³Vascular Surgery, Department of Surgery, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ⁴Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Internal Medicine, Department of Medicine, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ⁶Division of Rheumatology, Department of Medicine, Montreal, Canada
Background/Purpose: Giant Cell Arteritis (GCA) remains challenging to diagnose as false negative temporal artery biopsy (TAB) can occur. Color doppler ultrasonography (CDUS) of the temporal,…
Abstract Number: 2665 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice
Sebastian Unizony¹, Robert Spiera ², Jinglan Pei ³, Páris Sidiropoulos ³, Jennie Best ⁴ and John Stone ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Genentech, South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Approximately 50% of patients with giant cell arteritis (GCA) also have polymyalgia rheumatica (PMR) symptoms.1 The purpose of this study was to determine whether…
Abstract Number: 2666 • 2019 ACR/ARP Annual Meeting
Development and Outcome of Aortic Complications During Tocilizumab (TCZ) Treatment of GCA and Histopathologic Evidence of Residual Inflammation
Andrea Rubbert-Roth¹, Peter Karl Bode ², Thomas Langenegger ³, Claudia Pfofe ⁴, Thomas Neumann ⁵, Olaf Chan-Hi Kim ⁶ and Johannes von Kempis ⁷, ¹Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ²Institute of Pathology and Molecular Pathology, University Hospital of Zurich, Zuerich, Switzerland, ³Rheumatology Clinic Zug, Zug, Switzerland, ⁴Pathology Institute Triemli, Zurich, Zuerich, Switzerland, ⁵Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ⁶Department of Radiology, Kantonsspital St Gallen, St.Gallen, Switzerland, ⁷Division of Rheumatology, Kantonsspital St Gallen, St.Gallen, Switzerland
Background/Purpose: GCA may affect the aorta and lead to dissections and aortic aneurysms. TCZ treatment may control aortic inflammation as demonstrated by CRP normalization and…
Abstract Number: 2667 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tocilizumab in Giant Cell Arteritis: A Monocentric Real-life Experience
Elena Baldissera¹, Alessandro Tomelleri ¹, Corrado Campochiaro ², Silvia Sartorelli ³ and Lorenzo Dagna ¹, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ³Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy
Background/Purpose: Tocilizumab (TCZ) has recently been shown to be effective and safe for the treatment of patients with giant cell arteritis (GCA). Here we describe…
Abstract Number: 2668 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics and Pharmacodynamics of Tocilizumab in Combination with Prednisone Tapering in Patients with Giant Cell Arteritis: 3-Year Results from a Randomized Controlled Phase 3 Trial
Navita Malallieu¹, Min Bao ² and John Stone ³, ¹Roche Innovation Center, New York, NY, ²Genentech, South San Francisco, CA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Tocilizumab (TCZ) administered subcutaneously weekly or every 2 weeks with a 26-week prednisone taper (TCZ-QW or TCZ-Q2W) was superior to placebo given with a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].